N17
Conditions
Interventions
Group 1: In patients who develop AKI KDIGO stage 2/3 within 72h after cardiac surgery with cardiopulmonary bypass, urine samples are collected daily up to 7 days after inclusion for biomarker analyse
Sponsors
Universitätsklinikum MünsterKlinik für Anästhesiologie, operative Intensivmedizin und Schmerztherapie
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - patients with AKI defined as KDIGO stage2/3 within 72h after on-pump cardiac surgery - 18-90 years - informed consent
Exclusion criteria
Exclusion criteria: - Prior kidney transplant - dialysis dependent CKD - History of human deficiency virus (HIV) or hepatitis virus (Hepatitis C) - pregnancy or nursing period - off-pump heart surgery - hepatorenal syndrome
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Predictive value of CCL14 for persistent AKI within 72h. In addition, the primary endpoint is met if the criteria mortality or dialysis dependency are met. Persistent KDIGO stage 3 (yes/no) is defined as follows. For patients enrolled at stage 2, persistent severe AKI “yes” requires an AKI progression to stage 3 within 48 hours and a persistence at stage 3 for at least 72 hours; otherwise severe AKI is considered not persistent. For patients enrolled at stage 3, persistent severe AKI “yes” requires a persistence at stage 3 for 72 hours from the time of sample collection; otherwise severe AKI is considered not persistent | — |
Secondary
| Measure | Time frame |
|---|---|
| - MAKE at day 30 and 90 - renal recovery at day 30 and 90 - dialysis dependency at day 30 and 90 - mortality on Day 30 and 90 - persistent severe AKI min. 72 h - Length of hospital and ICU stay | — |
Countries
Germany
Contacts
Public ContactAlexander Zarbock
Universitätsklinikum Münster Klinik für Anästhesiologie, operative Intensivmedizin und Schmerztherapie
Outcome results
None listed